Cover Image
市場調查報告書

Eisai:產品平台分析

Eisai Co., Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224549
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
Eisai:產品平台分析 Eisai Co., Ltd. - Product Pipeline Review - 2016
出版日期: 2016年08月17日 內容資訊: 英文 181 Pages
簡介

Eisai是代表日本的製藥公司,從事成藥及藥物生產系統的研究開發,製造,行銷。同時也提供化學產品,食品成分·添加物,營養補充品,化妝品等產品。該公司的研究領域是以神經學,腫瘤學,血管反應,免疫反應,腸胃障礙,肌肉骨骼疾病等為對象。

本報告提供Eisai的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Eisai的基本資料

  • Eisai概要
  • 主要資訊
  • 企業資料

Eisai:R&D概要

  • 主要的治療範圍

Eisai:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Eisai:開發中產品概況

  • 最後階段的開發中產品
  • 臨床實驗階段的開發中產品
  • 初期階段的開發中產品

Eisai:藥物簡介

  • cinitapride
  • eribulin mesylate
  • lenvatinib
  • lorcaserin hydrochloride
  • mecobalamin
  • mitiglinide
  • perampanel
  • clevudine
  • donepezil hydrochloride Patch
  • (diclofenac sodium + eperisone)
  • avatrombopag
  • BAN-2401
  • decitabine
  • denileukin diftitox
  • donepezil hydrochloride
  • E-2609
  • E-3710
  • E-6005
  • E-7820
  • eritoran tetrasodium
  • fosravuconazole
  • indisulam
  • irofulven
  • lemborexant
  • rabeprazole sodium DR
  • Vaccine for Metastatic Melanoma
  • bexarotene
  • E-6011
  • E-6201
  • E-7449
  • golvatinib + lenvatinib
  • golvatinib tartrate
  • tazemetostat
  • E-2027
  • E-6007
  • E-7046
  • E-7090
  • E-7389LF
  • AT-791
  • E-1210
  • E-2072
  • E-2508
  • E-5539
  • E-6446
  • ER-358063
  • ER-409903
  • ER-410660
  • ER-417258
  • ER-886046
  • ER-901356
  • Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity
  • SJ-733
  • Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders
  • Small Molecule to Inhibit Cytidine Deaminase for Cancer
  • Small Molecule to Inhibit GWT1 Protein for Malaria
  • Small Molecules for Bacterial Infections
  • Small Molecules for Chagas 疾病
  • Small Molecules for Lymphatic Filariasis and Onchocerciasis
  • Small Molecules for Malaria
  • Small Molecules for Oncology
  • Small Molecules for Tuberculosis
  • TRI-4

Eisai:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Eisai:最近的開發平台趨勢

Eisai:暫停中的計劃

Eisai:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Eisai:企業發表

Eisai:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08118CDB

Summary

Global Markets Direct's, 'Eisai Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Eisai Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eisai Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Eisai Co., Ltd.
  • The report provides overview of Eisai Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Eisai Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Eisai Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Eisai Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Eisai Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Eisai Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Eisai Co., Ltd. Snapshot
    • Eisai Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Eisai Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Eisai Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Eisai Co., Ltd. - Pipeline Products Glance
  • Eisai Co., Ltd. - Late Stage Pipeline Products
  • Eisai Co., Ltd. - Clinical Stage Pipeline Products
  • Eisai Co., Ltd. - Early Stage Pipeline Products
  • Eisai Co., Ltd. - Drug Profiles
    • donepezil hydrochloride
    • eribulin mesylate
    • lenvatinib mesylate
    • lorcaserin hydrochloride
    • mitiglinide
    • perampanel
    • clevudine
    • mecobalamin
    • avatrombopag
    • fosravuconazole
    • lemborexant
    • BAN-2401
    • denileukin diftitox
    • E-2609
    • E-3710
    • E-7820
    • indisulam
    • Vaccine for Metastatic Melanoma
    • E-6011
    • E-6201
    • E-7449
    • golvatinib + lenvatinib
    • golvatinib tartrate
    • tazemetostat
    • donepezil hydrochloride Patch
    • E-2027
    • E-7046
    • E-7090
    • E-7389LF
    • SJ-733
    • AT-791
    • E-2072
    • E-2508
    • E-5539
    • E-6446
    • ER-358063
    • ER-410660
    • ER-886046
    • ER-901356
  • Small Molecule for Epilepsy
  • Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders
  • Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders
  • Small Molecule to Inhibit Cytidine Deaminase for Oncology
  • Small Molecule to Inhibit GWT1 Protein for Malaria
  • E-209
  • Small Molecules for Bacterial Infections
  • Small Molecules for Chagas Disease
  • Small Molecules for Lymphatic Filariasis and Onchocerciasis
  • Small Molecules for Malaria
  • Small Molecules for Oncology
  • Small Molecules for Tuberculosis
  • TRI-4
  • Eisai Co., Ltd. - Pipeline Analysis
    • Eisai Co., Ltd. - Pipeline Products by Target
    • Eisai Co., Ltd. - Pipeline Products by Route of Administration
    • Eisai Co., Ltd. - Pipeline Products by Molecule Type
    • Eisai Co., Ltd. - Pipeline Products by Mechanism of Action
  • Eisai Co., Ltd. - Recent Pipeline Updates
  • Eisai Co., Ltd. - Dormant Projects
  • Eisai Co., Ltd. - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Eisai Co., Ltd. - Company Statement
  • Eisai Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Eisai Co., Ltd., Key Information
  • Eisai Co., Ltd., Key Facts
  • Eisai Co., Ltd. - Pipeline by Indication, 2016
  • Eisai Co., Ltd. - Pipeline by Stage of Development, 2016
  • Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Eisai Co., Ltd. - Partnered Products in Pipeline, 2016
  • Eisai Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Eisai Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Eisai Co., Ltd. - Pre-Registration, 2016
  • Eisai Co., Ltd. - Filing rejected/Withdrawn, 2016
  • Eisai Co., Ltd. - Phase III, 2016
  • Eisai Co., Ltd. - Phase II, 2016
  • Eisai Co., Ltd. - Phase I, 2016
  • Eisai Co., Ltd. - Preclinical, 2016
  • Eisai Co., Ltd. - Discovery, 2016
  • Eisai Co., Ltd. - Pipeline by Target, 2016
  • Eisai Co., Ltd. - Pipeline by Route of Administration, 2016
  • Eisai Co., Ltd. - Pipeline by Molecule Type, 2016
  • Eisai Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Eisai Co., Ltd. - Recent Pipeline Updates, 2016
  • Eisai Co., Ltd. - Dormant Developmental Projects,2016
  • Eisai Co., Ltd. - Discontinued Pipeline Products, 2016
  • Eisai Co., Ltd., Subsidiaries

List of Figures

  • Eisai Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Eisai Co., Ltd. - Pipeline by Stage of Development, 2016
  • Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Eisai Co., Ltd. - Partnered Products in Pipeline, 2016
  • Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Eisai Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Eisai Co., Ltd. - Pipeline by Route of Administration, 2016
  • Eisai Co., Ltd. - Pipeline by Molecule Type, 2016
  • Eisai Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top